Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now

Regencell Bioscience (NASDAQ: RGC) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It started the 52-week period as a penny stock. Investors need to tread with caution and not get lured in by the massive price gain.Regencell describes itself as an early stage bioscience company. That basically means it's researching drugs it believes may have promise, but it hasn't found anything yet. This is a high-risk area of the pharmaceutical sector that only the most aggressive investors should consider. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool